Oral Disodium Cromoglycate Treatment of A topic Dermatitis

Fourteen adults and 10 children with active atopic dermatitis entered this double blind cross-over study of oral disodium cromoglycate (DSCG) (adults 200 mg qid, children 100 mg qid) compared with placebo. Oral DSCG and placebo were given for 6 weeks in random order. According to the investigators' assessments of eczema, significant differences between active and placebo were found after 6 weeks' treatment. DSCG being favoured (P < 0.05). No differences were detected in the investigators' assessment of lichenization and overall disease. No significant. Results form food allergic patients were similar to those from non-food allergic patients. Two patients reported possible side effects of arthralgia and urticaria respectively. There were no treatment effects on serum IgE values or any other laboratory data.